What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? data from a single-centre cohort

Annals of the Rheumatic Diseases

Volumn 73, Issue 9, 2014, Pages 1695-1699

  Takase, K ^a   Horton, S C ^a,b   Ganesha, A ^c   Das, S ^a,b   McHugh, A ^c   Emery, P ^a,b   Savic, S ^b,c   Buch, Maya H ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AUTOANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN G; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ADVERSE OUTCOME; AGED; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOASSAY; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEROCONVERSION; TREATMENT DURATION; VASCULITIS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; COHORT STUDIES; DNA; DRUG MONITORING; FEMALE; HUMANS; IMMUNOCONJUGATES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS; YOUNG ADULT;

EID: 84905179241     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205318     Document Type: Article

References (25)

1. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9:188-93.
2. Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M, et al. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013;25:56-64.
3. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibody to tumour necrosis factor. Arthritis Rheum 1993;36:1681-90. (Pubitemid 23360007)
4. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10. (Pubitemid 24317629)
5. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic ef ficacy of multiple intravenous infusion of anti-tumour necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63. (Pubitemid 28459913)
6. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of anti- bodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
7. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80. (Pubitemid 34178442)
8. Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003;30:2287-91. (Pubitemid 37221866)
9. Bingham SJ, Buch MH, Kerr MA, et al. Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthritis Rheum 2004;50:4072-3. (Pubitemid 39643958)
10. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-51.
11. Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006;73:710-13. (Pubitemid 44918417)
12. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007;86:242-51. (Pubitemid 47067483)
13. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009;48:716-20.
14. Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011;50:619-25.
15. Sokumbi O, Wetter DA, Makol A, et al. Vasculitis associated with tumor necrosis factor-alpha inhibitors. Mayo Clin Proc 2012;87:739-45.
16. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
17. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
18. van Gestel AM, Prevoo ML, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40. (Pubitemid 26036375)
19. Eriksson C, Engstrand S, Sundqvist KG, et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005;64:403-7. (Pubitemid 40283050)
20. Yukawa N, Fujii T, Kondo-Ishikawa S, et al. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis Res Ther 2011;13:R213.
21. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6. (Pubitemid 46999794)
22. Hoffmann JH, Hartmann M, Enk AH, et al. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol 2011;165:1355-8.
23. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21.
24. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
25. Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-speci fic neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.